TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2022. Revenues are expected to be ...
For the three months ended December 31, 2022, Escalade reported net income of $2.7 million, or $0.20 per diluted share. Sales declined due to softening consumer demand and excess inventories in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback